Partial Breast Versus no Irradiation for Women With Early Breast Cancer

Danish Breast Cancer Cooperative Group (DBCG)

Status

Enrolling

Conditions

Fibrosis Breast

Death

Distantly Metastatic Malignant Neoplasm

Local Neoplasm Recurrence

Telangiectasia

PROMs

Pain

Scar

Depigmentation/Hyperpigmentation of Skin

Treatments

Radiation: No partial breast irradiation

Study type

Interventional

Funder types

Other

Identifiers

NCT03646955

DBCG RT Natural Trial

Details and patient eligibility

About

All early breast cancer patients are offered adjuvant breast radiation therapy (RT) after breast conserving surgery for an early breast cancer. Breast cancer is heterogeneous, and selected patients have a very low gain from RT, whilst they still have risk of acute and late side effects from RT. This trial will try identify selection criteria for low risk breast cancer patients who can safely omit adjuvant RT without unacceptable high risk of local failure.

Full description

International standard of therapy is to provide adjuvant breast radiation therapy (RT) after breast conserving surgery for an early breast cancer to lower the risk of local and distant failures. However, breast cancer is a heterogeneous disease, and the gain from RT in selected low risk patients is low. RT may cause acute and late side effects, and some of these may be serious to the patient. Therefore, there is a need to tailor RT utilization to the individual recurrence risk and try identify patients who are unlikely to gain much risk reduction from RT, because those patients can then omit RT and thereby avoid late effects and over-treatment. At the present time there is no consensus as to define the selection criteria for patients who may omit RT.

Based on early results from the randomized DBCG RT PBI trial, external beam 40 Gy/15 fr partial breast irradiation (PBI) has been standard in Denmark since April 2016 for selected low risk breast cancer patients. Based on results from the UK IMPORT LOW trial, the 5 yr local recurrence risk using this technique for PBI is 0.5%, whilst 2% for developing a new contralateral breast cancer.

This trial will investigate if PBI can safely be omitted in selected low risk breast cancer patients without causing unacceptable high risk of local failure.

Enrollment

926 estimated patients

Sex

Female

Ages

60+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Female patient >=60 years

Primary tumour characteristics by conventional histopathology

unilateral and unifocal non-lobular histology grade 1-2
maximum microscopic size <=20mm
node negative determined by sentinel node or axillary lymph node dissection
estrogen receptor >=10% positive
HER2 negative (by IHC and/or in situ hybridization)
resection margin >=2 mm for invasive carcinoma and any ductal carcinoma in situ associated with the cancer

Surgical type is breast conservation

Performance status ECOG 0-2

No evidence of distant metastasis

Exclusion criteria

multifocal or multicentric invasive carcinoma or ductal carcinoma in situ
evidence of clinical or pathological T4 breast cancer
grade 3 malignancy
previous breast cancer or DCIS irrespective of disease-free interval
previous radiation therapy to the breast or thorax,
previous neoplasm within 5 years except carcinoma in situ of the cervix, endometrium or coli, melanoma in situ.
comorbidity precluding the patient from radiation therapy (e.g. cardiovascular or pulmonary disease, scleroderma, systemic lupus erythematosus).
mental/psychiatric disorder which precludes the patient from understanding the randomization and the follow up.
documented hereditary breast cancer or with high genetic risk of breast cancer
life expectancy <10 years